CNCE
$10.21
Concert Pharmaceutic
$.51
5.26%
CNCE
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.68)
Revenue:  N/A
Thursday
Nov 5
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CNCE reports earnings?
Beat
Meet
Miss

Where is CNCE's stock price going from here?
Up
Flat
Down
Stock chart of CNCE
Analysts
Summary of analysts' recommendations for CNCE
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalJohnson & JohnsonZoetisBristol-Myers SquibbUltragenyx PharmaceuticalCatalentMerck & Co.